Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of serum proteomic biomarkers for prediction of response to infliximab (a monoclonal anti-TNF antibody) treatment in rheumatoid arthritis: an exploratory analysis.
Ortea I, Roschitzki B, Ovalles JG, Longo JL, de la Torre I, González I, Gómez-Reino JJ, González A. Ortea I, et al. Among authors: ovalles jg. J Proteomics. 2012 Dec 21;77:372-82. doi: 10.1016/j.jprot.2012.09.011. Epub 2012 Sep 20. J Proteomics. 2012. PMID: 23000593 Free article. Clinical Trial.
Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study.
Ortea I, Roschitzki B, López-Rodríguez R, Tomero EG, Ovalles JG, López-Longo J, de la Torre I, González-Alvaro I, Gómez-Reino JJ, González A. Ortea I, et al. Among authors: ovalles jg. PLoS One. 2016 Apr 6;11(4):e0153140. doi: 10.1371/journal.pone.0153140. eCollection 2016. PLoS One. 2016. PMID: 27050469 Free PMC article.
Clinical and therapeutic management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: RADAR study.
Gomez-Centeno A, Rubio-Romero E, Ovalles JG, Manrique-Arija S, Marsal-Barril S, Amarelo-Ramos J, Del Pino-Montes J, Muñoz-Fernández S, Bustabad S, Barbazán-Álvarez C. Gomez-Centeno A, et al. Among authors: ovalles jg. Rheumatol Int. 2019 Dec;39(12):2015-2024. doi: 10.1007/s00296-019-04378-6. Epub 2019 Aug 8. Rheumatol Int. 2019. PMID: 31396685
Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER).
Torrente-Segarra V, Salman-Monte TC, Rúa-Figueroa Í, Del Campo V, López-Longo FJ, Galindo-Izquierdo M, Calvo-Alén J, Olivé-Marqués A, Mouriño-Rodríguez C, Horcada L, Bohórquez C, Montilla C, Salgado E, Díez-Álvarez E, Blanco R, Andreu JL, Fernández-Berrizbeitia O, Expósito L, Gantes M, Hernández-Cruz B, Pecondón-Español Á, Lozano-Rivas N, Bonilla G, Lois Iglesias A, Rubio-Muñoz P, Ovalles J, Tomero E, Boteanu A, Narvaez J, Freire M, Vela P, Quevedo-Vila V, Juan Mas A, Muñoz-Fernández S, Raya E, Moreno M, Velloso-Feijoo ML, Soler G, Vázquez-Rodríguez TR, Pego-Reigosa JM; RELESSER Study Group of the Spanish Society of Rheumatology (SER) and the Study Group of Systemic Autoimmune Diseases of the SER (EAS-SER). Torrente-Segarra V, et al. Semin Arthritis Rheum. 2020 Aug;50(4):657-662. doi: 10.1016/j.semarthrit.2020.05.016. Epub 2020 May 30. Semin Arthritis Rheum. 2020. PMID: 32505871 Free article.
Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?
Riancho-Zarrabeitia L, Martínez-Taboada VM, Rúa-Figueroa I, Alonso F, Galindo-Izquierdo M, Ovalles J, Olivé-Marqués A, Mena Vázquez N, Calvo-Alén J, Menor Almagro R, Tomero Muriel E, Uriarte Isacelaya E, Boteanu A, Andres M, Freire González M, Santos Soler G, Ruiz-Lucea ME, Ibáñez-Barceló M, Castellví I, Galisteo C, Quevedo Vila V, Raya E, Narváez J, Expósito L, Hernández Beriaín JA, Horcada L, Aurrecoechea E, Pego Reigosa JM. Riancho-Zarrabeitia L, et al. Clin Exp Rheumatol. 2021 May-Jun;39(3):555-563. doi: 10.55563/clinexprheumatol/9kxexc. Epub 2020 Aug 7. Clin Exp Rheumatol. 2021. PMID: 32828148 Free article.
Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality.
Riancho-Zarrabeitia L, Martínez-Taboada V, Rúa-Figueroa I, Alonso F, Galindo-Izquierdo M, Ovalles J, Olivé-Marqués A, Fernández-Nebro A, Calvo-Alén J, Menor-Almagro R, Tomero-Muriel E, Uriarte-Isacelaya E, Botenau A, Andres M, Freire-González M, Santos Soler G, Ruiz-Lucea E, Ibáñez-Barceló M, Castellví I, Galisteo C, Quevedo Vila V, Raya E, Narváez-García J, Expósito L, Hernández-Beriaín JA, Horcada L, Aurrecoechea E, Pego-Reigosa JM. Riancho-Zarrabeitia L, et al. Lupus. 2020 Oct;29(12):1556-1565. doi: 10.1177/0961203320950477. Epub 2020 Aug 17. Lupus. 2020. PMID: 32807021
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM; SENSCIS Trial Investigators. Distler O, et al. N Engl J Med. 2019 Jun 27;380(26):2518-2528. doi: 10.1056/NEJMoa1903076. Epub 2019 May 20. N Engl J Med. 2019. PMID: 31112379 Free article. Clinical Trial.